Baylor Research Institute

Sites wrestle with protocol design complexity

Wednesday, March 1, 2017

The growing complexity of protocols is resulting in longer cycle times, rising costs and increased pressures on staff and patients throughout the clinical trial process. Tufts Center for the Study of Drug Development (CSDD) studies have found that the number of endpoints, procedures and eligibility criteria of typical phase III protocols increased significantly during 2002-2012, and have continued to grow. These factors combine to increase costs and burdens on research teams.

[Read More]

Ultragenyx gains worldwide rights for Triheptanoin

Thursday, July 18, 2013

Ultragenyx, a privately held, clinical-stage biotechnology company, has expanded its exclusive license from Baylor Research Institute (BRI) in Dallas, Texas, to develop and commercialize triheptanoin outside North America. The global license includes rights to patents, patent applications and other intellectual property related to the composition and formulation of UX007, as well as its use in treating diseases including fatty acid oxidation disorders (FAOD), the lead indication being developed by the company.

[Read More]

Medical Research Funding at Baylor Still Strong

Wednesday, June 16, 2010

The Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute, received grants totaling nearly $35 million in 2009, despite an economy that’s seen a marked decrease in charitable giving and government grants.

[Read More]